NASDAQ:AGTC - Applied Genetic Technologies Stock Price, News, & Analysis

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Applied Genetic Technologies Corp (NASDAQ:AGTC) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.04. The biotechnology company earned $3.60 million during the quarter, compared to analysts' expectations of $6.41 million. Applied Genetic Technologies had a negative return on equity of 16.00% and a negative net margin of 65.96%. View Applied Genetic Technologies' Earnings History.

Applied Genetic Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, September, 12th 2018. View Earnings Estimates for Applied Genetic Technologies.

5 analysts have issued twelve-month price targets for Applied Genetic Technologies' stock. Their predictions range from $7.00 to $12.00. On average, they expect Applied Genetic Technologies' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 119.5% from the stock's current price. View Analyst Price Targets for Applied Genetic Technologies.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Genetic Technologies.

Some companies that are related to Applied Genetic Technologies include Surface Oncology (SURF), ADMA Biologics (ADMA), MeiraGTx (MGTX), Nantkwest (NK), Jounce Therapeutics (JNCE), Idera Pharmaceuticals (IDRA), Allena Pharmaceuticals (ALNA), Agenus (AGEN), Fennec Pharmaceuticals (FENC), Compugen (CGEN), Eiger Biopharmaceuticals (EIGR), Krystal Biotech (KRYS), Organovo (ONVO), Pluristem Therapeutics (PSTI) and Cidara Therapeutics (CDTX).

News coverage about AGTC stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.38 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Applied Genetic Technologies.

Applied Genetic Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.04%), Acadian Asset Management LLC (3.79%), Renaissance Technologies LLC (3.50%), BlackRock Inc. (1.84%), Municipal Employees Retirement System of Michigan (1.33%) and Point72 Asset Management L.P. (1.18%). Company insiders that own Applied Genetic Technologies stock include Ivana Magovcevic, Jeffrey D Chulay, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Institutional Ownership Trends for Applied Genetic Technologies.

AGTC stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Municipal Employees Retirement System of Michigan, BlackRock Inc. and Alambic Investment Management L.P.. View Insider Buying and Selling for Applied Genetic Technologies.

AGTC stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Marquette Asset Management LLC and Point72 Asset Management L.P.. Company insiders that have bought Applied Genetic Technologies stock in the last two years include Ivana Magovcevic, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Insider Buying and Selling for Applied Genetic Technologies.

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AGTC stock can currently be purchased for approximately $4.10.

Applied Genetic Technologies has a market capitalization of $75.16 million and generates $39.47 million in revenue each year. The biotechnology company earns $400,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Applied Genetic Technologies employs 72 workers across the globe.

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.